<DOC>
	<DOCNO>NCT01443429</DOCNO>
	<brief_summary>The PK safety profile examine follow single oral administration TRK-100STP ( 120 μg ) fasting condition patient renal impairment subject normal renal function .</brief_summary>
	<brief_title>A Pharmacokinetic Study TRK-100STP Japanese Patients With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>The eGFR 1 day study drug administration stipulate follow . Subjects normal renal function : ≥90 Patients mild renal impairment : ≥60 &lt; 90 Patients moderate renal impairment : ≥30 &lt; 60 Patients severe renal impairment : ≥15 &lt; 30 Patients dialysis Patients history undergoing renal transplantation Patients diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>TRK-100STP</keyword>
	<keyword>PK</keyword>
	<keyword>beraprost sodium</keyword>
	<keyword>Japanese male female</keyword>
	<keyword>Subjects mild/moderate/severe patient</keyword>
	<keyword>renal impairment</keyword>
</DOC>